These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice. Titelbaum DS; Engisch R; Schwartz ED; Napoli SQ; Sloane JA; Samaan S; Katz JD; Lathi ES J Neuroimaging; 2020 Nov; 30(6):917-929. PubMed ID: 32830899 [TBL] [Abstract][Full Text] [Related]
3. 7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. Zurawski J; Tauhid S; Chu R; Khalid F; Healy BC; Weiner HL; Bakshi R Mult Scler; 2020 Feb; 26(2):177-187. PubMed ID: 31714181 [TBL] [Abstract][Full Text] [Related]
4. No association between cortical lesions and leptomeningeal enhancement on 7-Tesla MRI in multiple sclerosis. Ighani M; Jonas S; Izbudak I; Choi S; Lema-Dopico A; Hua J; O'Connor EE; Harrison DM Mult Scler; 2020 Feb; 26(2):165-176. PubMed ID: 31573837 [TBL] [Abstract][Full Text] [Related]
5. Meningeal contrast enhancement in multiple sclerosis: Assessment of field strength, acquisition delay, and clinical relevance. Harrison DM; Allette YM; Zeng Y; Cohen A; Dahal S; Choi S; Zhuo J; Hua J PLoS One; 2024; 19(5):e0300298. PubMed ID: 38809920 [TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Absinta M; Cortese IC; Vuolo L; Nair G; de Alwis MP; Ohayon J; Meani A; Martinelli V; Scotti R; Falini A; Smith BR; Nath A; Jacobson S; Filippi M; Reich DS Neurology; 2017 Apr; 88(15):1439-1444. PubMed ID: 28283598 [TBL] [Abstract][Full Text] [Related]
7. Inversion Recovery Susceptibility Weighted Imaging With Enhanced T2 Weighting at 3 T Improves Visualization of Subpial Cortical Multiple Sclerosis Lesions. Beck ES; Gai N; Filippini S; Maranzano J; Nair G; Reich DS Invest Radiol; 2020 Nov; 55(11):727-735. PubMed ID: 32604385 [TBL] [Abstract][Full Text] [Related]
8. Association of MRI leptomeningeal enhancement with disability worsening in progressive multiple sclerosis: A clinical and post-mortem study. Vercellino M; Costantini G; Cogoni M; Lequio L; Sciortino P; De Negri F; Marasciulo S; Valentini C; Bosa C; Garelli P; Rolando A; Calvo A; Morana G; Cavalla P Mult Scler; 2023 Nov; 29(13):1526-1539. PubMed ID: 37740714 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. Zivadinov R; Ramasamy DP; Hagemeier J; Kolb C; Bergsland N; Schweser F; Dwyer MG; Weinstock-Guttman B; Hojnacki D AJNR Am J Neuroradiol; 2018 Apr; 39(4):642-647. PubMed ID: 29439125 [TBL] [Abstract][Full Text] [Related]
10. Leptomeningeal enhancement of myelin oligodendrocyte glycoprotein antibody-associated encephalitis: uncovering novel markers on contrast-enhanced fluid-attenuated inversion recovery images. Li L; Liu W; Cai Q; Liu Y; Hu W; Zuo Z; Ma Q; He S; Jin K Front Immunol; 2023; 14():1152235. PubMed ID: 37409120 [TBL] [Abstract][Full Text] [Related]
11. Leptomeningeal Enhancement at 7T in Multiple Sclerosis: Frequency, Morphology, and Relationship to Cortical Volume. Harrison DM; Wang KY; Fiol J; Naunton K; Royal W; Hua J; Izbudak I J Neuroimaging; 2017 Sep; 27(5):461-468. PubMed ID: 28464368 [TBL] [Abstract][Full Text] [Related]
12. Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. Bergsland N; Ramasamy D; Tavazzi E; Hojnacki D; Weinstock-Guttman B; Zivadinov R AJNR Am J Neuroradiol; 2019 Apr; 40(4):620-625. PubMed ID: 30872420 [TBL] [Abstract][Full Text] [Related]
13. Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement. Bhargava P; Wicken C; Smith MD; Strowd RE; Cortese I; Reich DS; Calabresi PA; Mowry EM Mult Scler Relat Disord; 2019 May; 30():136-140. PubMed ID: 30771580 [TBL] [Abstract][Full Text] [Related]
14. Focal cortical atrophy following transient meningeal enhancement in a progressive multiple sclerosis. Bonnan M; Money P; Desblache P; Marasescu R; Puvilland LM; Demasles S; Dahan C; Krim E; Tucholka A; Doyle S; Barroso B Neurol Sci; 2021 May; 42(5):1959-1961. PubMed ID: 32995987 [TBL] [Abstract][Full Text] [Related]
15. Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study. Tzanetakos D; Tzartos JS; Vakrakou AG; Breza M; Velonakis G; Stathopoulos P; Pantou E; Markakis I; Papadimitriou D; Karavasilis E; Toulas P; Evangelopoulos ΜE; Koutsis G; Anagnostouli M; Stefanis L; Kilidireas C Mult Scler; 2022 Apr; 28(5):718-729. PubMed ID: 34410179 [TBL] [Abstract][Full Text] [Related]
19. A pilot trial of ocrelizumab for modulation of meningeal enhancement in multiple sclerosis. Dahal S; Allette YM; Naunton K; Harrison DM Mult Scler Relat Disord; 2024 Jan; 81():105344. PubMed ID: 38035495 [TBL] [Abstract][Full Text] [Related]
20. Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis. Ineichen BV; Tsagkas C; Absinta M; Reich DS Neuroimage Clin; 2022; 33():102939. PubMed ID: 35026625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]